Incidence of the BIM polymorphism is 50 out of 411 patients, or 12.2%. Abbreviations: Ma-Spore, Malaysia- Singapore; MRD, minimal residual disease; NCI, National Cancer Institute; PCR, polymerase chai
Combining venetoclax, a selective BCL-2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL-2 inhibitor, may potentiate therapeutic BCL-2 and BCL XL inhibition without dose-limiting thrombocytopenia ass
